BioSpace News Archive

Twist Bioscience Corporation announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing.

Emergent BioSolutions Inc. remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies.

Molecular Templates, Inc. announced it has entered into a definitive amended and restated securities purchase agreement with certain healthcare investors that will provide $9.5 million in gross proceeds to MTEM through the closing of the second tranche of its previously announced July 2023 private placement and purchase agreement on amended terms.

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the appointment of Colleen Sjogren as Chief Commercial Officer.

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Aurion Biotech today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Biodexa Pharmaceuticals, an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment of Diffuse Midline Glioma in pediatric patients and for Recurrent Glioblastoma in adults; two aggressive brain cancers with universally poor prognoses.

GlobeStar Therapeutics Corporation, is a clinical stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis and other neurological diseases, including but not limited to Rheumatoid Arthritis, released on March 11, 2024 its fiscal year first quarter financials for the quarter ended 12/31/2023.

Tenax Therapeutics, Inc. (Nasdaq: TENX) announced full year 2023 financial results, and provided clinical development and business updates.

CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. announced that the U.S. Food and Drug Administration has approved Vafseo tablets for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.